Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Anavex Life Sciences

  • Christopher U. Missling, Anavex Life Sciences Corp.

Anavex utilizes precision genetic medicine to treat severe and devastating neurological disorders and

is focusing on rare diseases with no available therapy (Rett syndrome) and high risk CNS patient populations (Parkinson's Disease, Alzheimer's Disease)

  • Date:Monday, February 11
  • Time:1:30 PM - 1:45 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23542
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Goal for Presentation:Educating the Audience on our Latest Developments
  • Company Website:https://www.anavex.com/
  • Company HQ City:New York
  • Company HQ State:New York
  • Company HQ Country:United States
  • Ticker:AVXL
  • Exchange:Nasdaq
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development:ANAVEX2-73
  • Development Phase of Primary Product:Phase III
Speakers
Christopher U. Missling
Anavex Life Sciences Corp.
Back